Protara Therapeutics Inc (NAS:TARA)
$ 5.51 0.01 (0.18%) Market Cap: 189.10 Mil Enterprise Value: 112.00 Mil PE Ratio: 0 PB Ratio: 1.39 GF Score: 40/100

Protara Therapeutics Inc at Guggenheim Healthcare Talks Oncology Day Transcript

Feb 09, 2023 / 04:20PM GMT
Release Date Price: $3.38 (+1.20%)
Charles Zhu
Guggenheim Partners - Analyst

Good morning. I'm Charles Zhu, one of the senior biotech analysts here at Guggenheim Securities. For our next session, we are joined by Protara, specifically Jackie and Jathin from Protara. I want to thank you very much for your participation at our conference today.

Questions & Answers

Charles Zhu
Guggenheim Partners - Analyst

Perhaps just to kick us off, could you provide us with a brief overview of your company platform and pipeline, please?

Jackie Zummo
Protara Therapeutics, Inc. - Co-founder, Senior Vice President & Chief Scientific Operations Officer

Sure. Thanks for having us here today. So Protara is a New York City-based biopharm company. We take the approach of providing advanced scientific approaches to establish mechanisms. Our lead program is TARA-002. We are initially looking at that in non-muscle-invasive bladder cancer. TARA-002 is a immune potentiator that we are also looking at it in the rare pediatric disease, lymphatic malformations.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot